Figure 1.

Silencing of SND1 increases the sensitivity of BC cells to cisplatin. (A) The IC₅₀ values of the response of BC cells to cisplatin. (B) Treatment of T24/R, T24, 5637/R and 5637 cells with various concentrations of cisplatin for 24 h, and assessment of their cellular viabilities. (C) RNA sequencing analysis of gene expression in T24/R and T24 cells. (D) mRNA levels of SND1 were assessed by reverse transcription-quantitative polymerase chain reaction in T24, T24/R, 5637 and 5637/R cells. (E) Western blotting was used to assess the protein levels of SND1. (F) mRNA levels of SND1 in various BC cells. (G) Protein levels of SND1 in various BC cells. (H) T24/R and 5637/R cells were transfected as indicated, and the mRNA levels of SND1 were assessed. (I) T24/R and 5637/R cells were transfected as indicated, and protein levels of SND1 were determined. (J) T24/R and 5637/R cells were transfected as indicated, and treated with various concentrations of cisplatin for 24 h, and their cellular viabilities were assessed. Data are presented as the mean ± standard deviation. **P<0.01. SND1, staphylococcal nuclease and tudor domain containing 1; BC, bladder cancer; sh, short hairpin RNA; NC, negative control.